It’s the first new class of pain treatment approved in more than 20 years, Vertex says.
Published: Jan. 31, 2025 at 4:35 a.m. ET
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.
It’s the first new class of pain treatment approved in more than 20 years, Vertex said in a press statement late Thursday. After closing the regular session down 0.7%, shares of the pharmaceutical company VRTX rose 8.3%.
About the Author
